Phase 1 N=50 Open-label Safety and Tolerability Study of CoVaccine HT™ in Healthy Volunteers
Vaccine
Primary: Safety Events — 20; 0; 40; 50 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=41 A Study of OsrHSA in Adult Healthy Male and Female Volunteers
Ascites Hepatic
Primary: Incidence of Treatment-Emergent Adverse Events — 1; 0; 2; 1 Participants
N/A N=37 Pilot Investigation of a Multinutrient Supplement on Skin Aging and Aging Metabolites in Healthy Women
Skin Diseases
Primary: Fold Change in Long Chain Fatty Acids — 1; 0.76 Fold Change in long chain fatty acids
Phase 1 N=24 Effect of Low-Fat Food on Pexidartinib Pharmacokinetics in Healthy Volunteers
Healthy Volunteers
Primary: Maximum Observed Concentration in Plasma (Cmax) of Pexidartinib — 4580; 7090; 3870 ng/mL
N/A N=978 Health Education Model Led by Community Health Volunteers.
Schistosomiasis · Health Education
Primary: Change in Infection Rate — 47; 35; 3; 6 Number of Participants with S. haematobi
N/A N=329 Breast Health Education for Underserved Latino Women
Breast Cancer
Primary: The Frequencies of Paired Responses to Identical Questions on a Survey Administered at Two Timepoints: Before the Health Education Program (i.e., Baseline) and…
N/A N=200 Urinalysis Results in Healthy Individuals
Asymptomatic Bacteriuria · Asymptomatic Pyuria
Primary: False Positive Urine — 6; 40 Participants
N/A N=22 Survival and Recovery of Radio-labeled Platelets Derived From Mirasol-treated Whole Blood
Blood Safety
Primary: Platelet 24-hour Relative Recovery — 43.31; 52.01 Percentage of platelet count
N/A N=42 HEALTHY (Health Education Adolescent Leadership Training to Help Youth) Leaders
Stress
Primary: Number of Participants Reporting Pediatric Symptoms as Assessed by the Pediatric Symptom Checklist-17 (PSC-17) — 3; 2; 4; 3 participants
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
Phase 4 N=44 Eovist vs. Dotarem Healthy Volunteer MRI
Transient Severe Arterial Phase Motion
Primary: Subject Breath Hold Capacity, as Measured by Number of Seconds a Subject Can Hold His/Her Breath — 28; 38; 35 seconds
N/A N=7,314 Increasing Engagement With a Healthy Food Benefit
Purchasing Behaviors · Nutrition
Primary: Monthly % Healthy Food Expenditure — 24.8; 26.8; 24.9; 25.7 Percentage of money per month
Phase 1 N=12 A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin
Pharmacokinetics · Healthy Volunteers
Primary: Area Under the Concentration-Time Curve From Time Zero (0) Extrapolated to Infinity (AUCinf) of Rosuvastatin in Period 1 and 2 — 58.62; 72.78 Nanogram*hour per milliliter
N/A N=80 Impact of Volunteer Peer-Led Intervention for Weight Control in Primary Care
Weight Loss
Primary: Percent Change in Weight — -1.27; -2.76 percent weight change
N/A N=13 Clinical Trial Testing the BioSerenity Pulse Oximeter (EOXY) Efficacy, Performance and Safety in Healthy Volunteer
Healthy
Primary: Percentage SPO2 Accuracy Root-Mean Square (ARMS) at Forehead Position — 3.91; 3.08; 3.36; 2.85 percentage of ARMS (accuracy)
N/A N=148 Healthy, Immunized Communities Study
Vaccine Hesitancy · Communicable Diseases in Children
Primary: Percentage of Participants With Intent to Vaccinate Adolescent Child (Tdap, MCV, HPV) — 74.3; 83.3; 97.9; 93.0 percentage of participants
Phase 1 N=62 Phase 1 Study of ELX-02 in Healthy Adult Subjects
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
N/A N=2,105 The United States Healthy Living Study
Colo-rectal Cancer
Primary: Intention to Talk to Doctor About Colorectal Cancer Screening — 4.14; 4.0; 3.59; 3.48 units on a scale
Phase 1 N=66 Phase 1 Study for IPG11406 in Health Volunteer
Inflammatory Bowel Diseases
Primary: Safety Indicators：Adverse Event — 1; 3; 2; 3 Participants
N/A N=291 The Helping Older People Engage Project: Improving Social Well-Being in Later Life
Loneliness · Quality of Life
Primary: Loneliness — 44.36; 44.10 units on a scale — p=.896
Phase 1 N=4 Challenge Infection of Healthy Adult Volunteers With RSV A2
Upper Respiratory Tract Infections
Primary: Participants With Detectable RSV Shedding in Nasopharyngeal Wash — 2; 4 Participants
Phase 2 N=25 Positron-Emission Tomography With Vesicular Monoamine Transporter Ligand ([18F]-DTBZ) In Healthy Elderly And Young Subjects
Healthy
Primary: Age-Dependent Change in Striatal 18F-DTBZ Uptake of Healthy Subjects. — 0.05 SUVR
Phase 4 N=54 The Effects of Anti-Inflammatory Treatment on Insulin Resistance in Healthy Volunteers
Type 2 Diabetes · Diabetes
Primary: Change in Fasting Plasma Glucose Concentration — 4.7; 0.0 mmol/l
Phase 1 N=16 Study to Evaluate Safety and Activity of TRL345 in Healthy Volunteers
Healthy Volunteers
Primary: Incidence of Abnormal Physical Exam Findings — 0; 0; 0 Participants
N/A N=18 Production of a Device to Obtain Continuous Ambulatory Vestibular Assessment (CAVA) - Healthy Volunteer Trial
Optokinetic Nystagmus
Primary: Sensitivity and Specificity of a Computer Algorithm to Detect Artificially Induced Nystagmus — 99.1; 98.6 Percent
N/A N=13 90-Day Cobalt Supplementation Study to Investigate the Cobalt Body Burden in Ten Healthy Adult Volunteers
Cobalt Biokinetics · Safety of Cobalt Dietary Supplementation
Primary: Cobalt Whole Blood Concentrations — 14.6; 7.4; 33.9; 8.5 µg Co/L
N/A N=200 Genetic Risk and Health Coaching for Type 2 Diabetes and Coronary Heart Disease
Coronary Heart Disease, Susceptibility to, 5 · Prediabetic State
Primary: Dietary Intake as Measured by Percent Energy From Fat — 33.75; 34.9; 33.72; 35.05 percent energy from fat — p=0.1073
N/A N=30 Investigation of New Intermittent Catheters in Healthy Volunteers
Retention, Urinary
Primary: Residual Urine at 1st Flow-stop — 35.0; 1.1; 0.2; 37.0 mL — p=0.010
N/A N=9 Explorative Clinical Study on the Performance and Acceptance of New Intermittent Catheters in Healthy Volunteers
Compliance, Patient
Primary: Urine Flow Rate — 5.43; 5.47; 2.88 mL per second
Phase 1 N=8 First-in-Human Study to Assess the Safety, Tolerability and Pharmacokinetics of MMV367
Malaria,Falciparum
Primary: Number of Treatment-Emergent Adverse Events (TEAEs) — 1; 4; 5; 1 Number of events